目的 系统评价新型口服抗凝药(达比加群酯、利伐沙班、阿哌沙班及依度沙班)用于非瓣膜性房颤治疗的有效性和安全性。方法 计算机检索截止2016年9月,在Pubmed, Embase, Medline, Cochrane, ClinicalTrials.gov, Web of Science, 中国知网、万方及维普数据库中检索关于新型口服抗凝药用于非瓣膜性房颤治疗的随机对照研究,根据纳入标准和排除标准对文献进行筛选和质量评价,使用Rev Man 5.3和Stata 13.1软件对数据进行网络Meta分析。结果 共纳入17篇随机对照研究,总计83 561例患者。网络Meta分析结果显示,新型口服抗凝药预防全因死亡率的作用按照由高至低依次排序为利伐沙班,阿哌沙班,依度沙班,达比加群酯;治疗卒中和体循环栓塞的作用按照由高至低依次排序为利伐沙班,达比加群酯,阿哌沙班,依度沙班;治疗缺血性卒中的作用按照由高至低依次排序为利伐沙班,阿哌沙班,达比加群酯,依度沙班;严重出血率按照由低至高依次排序为依度沙班,阿哌沙班,达比加群酯,利伐沙班;颅内出血率按照由低至高依次排序为达比加群酯,依度沙班,阿哌沙班,利伐沙班;心肌梗死率按照由低至高依次排序为利伐沙班,阿哌沙班,依度沙班,达比加群酯。所有结局指标的不一致性检测表明,直接比较与间接比较无显著的不一致性。异质性检验显示研究间不存在统计学异质性。结论 充分比较新型口服抗凝药的有效性、安全性及经济性,阿哌沙班排序最佳,可考虑首选。
Abstract
OBJECTIVE To evaluate the efficacy and safety of new oral anticoagulants (dabigatran etexilate, rivaroxaban, apixaban, edoxaban) in the treatment of non-valvular atrial fibrillation. METHODS The randomized controlled trials about new oral anticoagulants in the treatment of non-valvular atrial fibrillation, which had been published from the time of library foundation to March 2016 were collected from Pubmed, Embase, Medline, Cochrane, ClinicalTrials.gov, Web of Science, CNKI, Wanfang database, VIP database according to the following criterias. At the same time quality of the trials was evaluated and the results of studies were analyzed using Rev Man 5.3 software and Stata 13.1 software. RESULTS Seventeen randomized controlled trials were included, involving 83 561 patients. Network Meta-analysis showed that in the prevention of all-cause mortality, the optimal sorting order of new oral anticoagulants was rivaroxaban, apixaban, edoxaban, dabigatran etexilate; in the prevention of the incidence of stroke and systemic embolism, the optimal sorting order of new oral anticoagulants was rivaroxaban, dabigatran etexilate, apixaban, edoxaban; in the prevention of the incidence of ischemic stroke, the optimal sorting order of new oral anticoagulants was rivaroxaban, apixaban, dabigatran etexilate, edoxaban; the incidence of major bleeding for the optimal sorting order of new oral anticoagulants was edoxaban, apixaban, dabigatran etexilate, rivaroxaban; the incidence of intracranial bleeding for the optimal sorting order of new oral anticoagulants was dabigatran etexilate, edoxaban, apixaban, rivaroxaban; the incidence of myocardial infarction for the optimal sorting order of new oral anticoagulants was rivaroxaban, apixaban, edoxaban, dabigatran etexilate. The inconsistency of all the outcomes indicated that there was no significant difference between direct comparison and indirect comparison. In addition, there was no statistical heterogeneity among studies. CONCLUSION Through analysis the effectiveness, safety and economy of new oral anticoagulants, apixaban has the best sort and should be used in preference.
关键词
新型口服抗凝药物 /
房颤 /
有效性 /
安全性 /
网络Meta分析
{{custom_keyword}} /
Key words
new oral anticoagulant atrial fibrillation /
efficacy /
safety /
network Meta-analysis
{{custom_keyword}} /
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] VERDECCHIA P, ANGELI F, BARTOLINI C, et al. Safety and efficacy of non-vitamin K oral anticoagulants in non-valvular atrial fibrillation: a Bayesian Meta-analysis approach[J]. Expert Opin Drug Saf, 2015, 14(1):7-20.
[2] JANUARY C T, WANN L S, ALPERT J S, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society[J]. Circulation, 2014, 130(23):2071-2104.
[3] DA S R. Novel oral anticoagulants in non-valvular atrial fibrillation[J]. Cardiovasc Hematol Agents Med Chem, 2014, 12(1):3-8.
[4] PROVIDENCIA R, GROVE E L, HUSTED S, et al. A Meta-analysis of phase III randomized controlled trials with novel oral anticoagulants in atrial fibrillation: comparisons between direct thrombin inhibitors vs. factor Xa inhibitors and different dosing regimens[J]. Thromb Res, 2014, 134(6):1253-1264.
[5] GHATE S R, BISKUPIAK J E, YE X, et al. Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis[J]. Ann Pharmacother, 2011, 45(6):701-712.
[6] MANNUCCI P M, FRANCHINI M. Old and new anticoagulant drugs: a minireview[J]. Ann Med, 2011, 43(2):116-123.
[7] O′DELL K M, IGAWA D, HSIN J. New oral anticoagulants for atrial fibrillation: a review of clinical trials[J]. Clin Ther, 2012, 34(4):894-901.
[8] BRUINS S K, BERGE E. Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation[J]. Cochrane Database Syst Rev, 2013, 8:CD008980.
[9] HIGGINS J P T, GREEN S. Cochrane handbook for systematic reviews of interventions version 5.1.0[M/OL]. The Cochrane Collaboration, 2011[2015-06]. http://handbook. cochrane. org/.
[10] TURNER R M, DAVEY J, CLARKE M J, et al. Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews[J]. Int J Epidemiol, 2012, 41(3):818-827.
[11] HIGGINS J P, JACKSON D, BARRETT J K, et al. Consistency and inconsistency in network meta-analysis: concepts and models for multi-arm studies[J]. Res Synth Methods, 2012, 3(2):98-110.
[12] LIU X, HUANG H, YU J, et al. Warfarin compared with aspirin for older Chinese patients with stable coronary heart diseases and atrial fibrillation complications[J]. Int J Clin Pharmacol Ther, 2014, 52(6):454-459.
[13] MAO L, LI C, LI T, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation[J]. Vascular, 2014, 22(4):252-258.
[14] GIUGLIANO R P, RUFF C T, BRAUNWALD E, et al. Edoxaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2013, 369(22):2093-2104.
[15] CHEN K P, HUANG C X, HUANG D J, et al.Anticoagulation therapy in Chinese patients with non-valvular atrial fibrillation: a prospective, multi-center, randomized, controlled study[J]. Chin Med J (Engl Ed)(中华医学杂志英文版), 2012, 125(24):4355-4360.
[16] YAMASHITA T, KORETSUNE Y, YASAKA M, et al.Randomized, multicenter, warfarin-controlled phase Ⅱ study of edoxaban in Japanese patients with non-valvular atrial fibrillation[J]. Circ J, 2012, 76(8):1840-1847.
[17] HORI M, MATSUMOTO M, TANAHASHI N, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation-the J-ROCKET AF study-[J]. Circ J, 2012, 76(9):2104-2111.
[18] CONNOLLY S J, EIKELBOOM J, JOYNER C, et al. Apixaban in patients with atrial fibrillation[J]. N Engl J Med, 2011, 364(9):806-817.
[19] GRANGER C B, ALEXANDER J H, MCMURRAY J J, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2011, 365(11):981-992.
[20] PATEL M R, MAHAFFEY K W, GARG J, et al.Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011, 365(10):883-891.
[21] OGAWA S, SHINOHARA Y, KANMURI K. Safety and efficacy of the oral direct factor xa inhibitor apixaban in Japanese patients with non-valvular atrial fibrillation[J]. Circ J, 2011, 75(8):1852-1859.
[22] CHUNG N, JEON H K, LIEN L M, et al. Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillation[J]. Thromb Haemost, 2011, 105(3):535-544.
[23] WEITZ J I, CONNOLLY S J, PATEL I, et al. Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation[J]. Thromb Haemost, 2010, 104(3):633-641.
[24] CONNOLLY S J, EZEKOWITZ M D, YUSUF S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361(12):1139-1151.
[25] EZEKOWITZ M D, REILLY P A, NEHMIZ G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO study)[J]. Am J Cardiol, 2007, 100(9):1419-1426.
[26] MANT J, HOBBS F D, FLETCHER K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA):a randomised controlled trial[J]. Lancet, 2007, 370(9586):493-503.
[27] RASH A, DOWNES T, PORTNER R, et al. A randomised controlled trial of warfarin versus aspirin for stroke prevention in octogenarians with atrial fibrillation (WASPO)[J]. Age Ageing, 2007, 36(2):151-156.
[28] A dose response study of dabigatran etexilate (BIBR 1048) in pharmacodynamics and safety in patients with non-valvular atrial fibrillation in comparison to warfarin [DB/OL]. clinicaltrials.gov, 2014[2016-3].https://www.clinicaltrials.gov/ct2/show/NCT01136408.
[29] HIGGINS J P T, GREEN S. Cochrane handbook for systematic reviews of interventions version 5.1.0[M/OL]. The Cochrane Collaboration, 2011[2016-3]. http://handbook.cochrane.org/.
[30] SHEHAB A, ELNOUR A A, BHAGAVATHULA A S, et al. Novel oral anticoagulants and the 73rd anniversary of historical warfarin[J]. J Saudi Heart Assoc, 2016, 28(1):31-45.
[31] MANNUCCI P M, FRANCHINI M. Old and new anticoagulant drugs: a minireview[J]. Ann Med, 2011, 43(2):116-123.
[32] GOEL R, SRIVATHSAN K. Newer oral anticoagulant agents: a new era in medicine[J]. Curr Cardiol Rev, 2012, 8(2):158-165.
[33] Chinese Journal of Cardiology thrombosis evidence-based group. Chinese experts recommend the use of new oral anticoagulants in non-valvular atrial fibrillation[J]. Chin J Cardiol(中华心血管病杂志), 2014, 42(5):362-369.
[34] MEGA J L, SIMON T. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments[J]. Lancet, 2015, 386(9990):281-291.
[35] GOEL R, SRIVATHSAN K. Newer oral anticoagulant agents: a new era in medicine[J]. Curr Cardiol Rev, 2012, 8(2):158-165.
[36] VILCHEZ J A, GALLEGO P, LIP G Y. Safety of new oral anticoagulant drugs: a perspective[J]. Ther Adv Drug Saf, 2014, 5(1):8-20.
[37] ROCKET A F. Study Investigators. Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation: rationale and design of the ROCKET AF study[J]. Am Heart J, 2010, 159(3):340-347.
[38] BAYER HEALTH CARE A G. XARELTO (rivaroxaban) tablets: prescribing information. USA [EB/OL]. [2017-01-09]. http://www.bayer.com/.
[39] RAGHAVAN N, FROST C E, YU Z, et al. Apixaban metabolism and pharmacokinetics after oral administration to humans[J]. Drug Metab Dispos, 2009, 37(1):74-81.
[40] SCHULMAN S. New oral anticoagulant agents-general features and outcomes in subsets of patients[J]. Thromb Haemost, 2014, 111(4):575-582.
[41] DE CATERINA R, KRISTENSEN S D, RENDA G. New anticoagulants for atrial fibrillation[J]. J Cardiovasc Med(Hagerstown), 2009, 10(6):446-453.
[42] GRAF L, TSAKIRIS D A. Anticoagulant treatment: the end of the old agents?[J]. Swiss Med Wkly, 2012, 142: w13684.
[43] SAVAYSA (edoxaban) tablets: prescribing information. USA [EB/OL]. [2017-01-09]. http://www. daiichisankyo. com/.
[44] MESSORI A, FADDA V, GATTO R, et al. New oral anticoagulants in acute coronary syndrome: is there any advantage over existing treatments?[J]. Int Cardiovasc Res J, 2014, 8(3):124-126.
[45] Boehringer Ingelheim Pharmaceuticals, Inc. PRADAXA (dabigatran etexilate mesylate) capsules: prescribing information. USA[EB/OL]. [2017-01-09]. https://www.pradaxa.com/.
[46] Bristol-Myers Squibb Company & Pfizer, Inc. ELIQUIS (apixaban) tablets: prescribing information. USA[EB/OL]. [2017-01-09]. http://www.bms.com/pages/default.aspx/.
[47] SCAGLIONE F. New oral anticoagulants: comparative pharmacology with vitamin K antagonists[J]. Clin Pharmacokinet, 2013, 52(2):69-82.
[48] HURLEN M, ABDELNOOR M, SMITH P, et al.Warfarin, aspirin, or both after myocardial infarction[J]. N Engl J Med, 2002, 347(13):969-974.
[49] LIP G Y, LANE D A. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?[J]. Am J Med, 2010, 123(9):785-789.
[50] LANITIS T, COTTE F E, GAUDIN A F, et al. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin[J]. J Med Econ, 2014, 17(8):587-598.
[51] WISLOFF T, HAGEN G, KLEMP M. Economic evaluation of warfarin, dabigatran, rivaroxaban, and apixaban for stroke prevention in atrial fibrillation[J]. Pharmacoeconomics, 2014, 32(6):601-612.
[52] LIP G Y, LANITIS T, KONGNAKORN T, et al. Cost-effectiveness of apixaban compared with edoxaban for stroke prevention in nonvalvular atrial fibrillation[J]. Clin Ther, 2015, 37(11):2476-2488.
{{custom_fnGroup.title_cn}}
脚注
{{custom_fn.content}}
PDF(4470 KB)
